In this context, a recent meta-analysis in pre-treated non-small-cell lung cancer patients indicated a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors [26]; however, in the absence of a direct comparison between anti-PD-1 and anti-PD-L1, no definitive conclusions are available, and we should consider all groups of ICIs to be of equal efficacy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.